All 1 Debates between Ronnie Cowan and Seema Kennedy

Medical Cannabis under Prescription

Debate between Ronnie Cowan and Seema Kennedy
Monday 20th May 2019

(5 years, 5 months ago)

Commons Chamber
Read Full debate Read Hansard Text Read Debate Ministerial Extracts
Seema Kennedy Portrait Seema Kennedy
- Hansard - - - Excerpts

I recognise the deep pain that families are going through, and I do take the point about the great frustration and desperation of the families. What I would say is that we have asked for more evidence, and we are working with everybody necessary to try to get this done as quickly as possible. NICE is internationally recognised for its robust and evidence-based evaluations and guidelines.

Ronnie Cowan Portrait Ronnie Cowan
- Hansard - -

I have two families in my constituency whose children are both suffering from epilepsy. They are taking Bedrolite today, and the families know it is beneficial for their kids. That is anecdotal evidence, but it is in their houses and they can see it working. The prescriptions for the sources they have will run out in June and in July. Can the Minister tell me what I should say to those parents when their kids’ prescriptions run out?

Seema Kennedy Portrait Seema Kennedy
- Hansard - - - Excerpts

I do not feel able to comment on a specific issue when I am not a doctor, a clinician or a scientist—

Ronnie Cowan Portrait Ronnie Cowan
- Hansard - -

As a parent?

Seema Kennedy Portrait Seema Kennedy
- Hansard - - - Excerpts

Of course I could as a parent, but again, I am not a doctor, and I am not here to make that call. What I would say is that I am very happy to meet the hon. Gentleman to get more of the facts he is presenting to me.

What is needed to support such prescription is evidence of efficacy, and for public funding evidence of cost-efficacy. That is the system we apply to all medicines and medical devices in the UK, and cannabis should not be treated any differently. The current evidence base has been summarised by the professional bodies in their interim clinical guidance, and it will be further examined and reported on by NICE shortly.